Hormone receptor (HR)-positive, HER2-negative advanced female breast cancer

Hormone receptor (HR)-positive, HER2-negative advanced female breast cancer is an invasive malignancy originating in the female mammary epithelium that has progressed to locally advanced, unresectable disease or distant metastases (Stage III–IV) Although this subtype accounts for the majority of female breast cancer diagnoses and maintains a reliance on hormone-mediated pathways, advanced disease represents an aggressive, largely incurable systemic stage characterized by eventual therapeutic res...

Hormone receptor (HR)-positive, HER2-negative advanced female breast cancer is an invasive malignancy originating in the female mammary epithelium that has progressed to locally advanced, unresectable disease or distant metastases (Stage III–IV) Pathophysiologically, the tumor cells express estrogen receptors, progesterone receptors, or both, which drive oncogenic cell proliferation and survival in response to endocrine signaling

Hormone receptor (HR)-positive, HER2-negative advanced female breast cancer is an invasive malignancy originating in the female mammary epithelium that has progressed to locally advanced, unresectable disease or distant metastases (Stage III–IV) Although this subtype accounts for the majority of female breast cancer diagnoses and maintains a reliance on hormone-mediated pathways, advanced disease represents an aggressive, largely incurable systemic stage characterized by eventual therapeutic res...

Pathophysiologically, the tumor cells express estrogen receptors, progesterone receptors, or both, which drive oncogenic cell proliferation and survival in response to endocrine signaling

Concurrently, these malignant cells do not overexpress human epidermal growth factor receptor 2 (HER2) protein or exhibit *ERBB2* gene amplification

Although this subtype accounts for the majority of female breast cancer diagnoses and maintains a reliance on hormone-mediated pathways, advanced disease represents an aggressive, largely incurable systemic stage characterized by eventual therapeutic resistance and metastatic spread to sites such as bone, viscera, or distant lymph nodes